The pharmaceutical industry is pushing the boundaries of the chemical drug space in search of new and more effective compounds. However, many of these new molecules have properties that make them difficult to develop, including challenging physiochemical characteristics. As a result, the number of poorly soluble drugs in the pipeline is increasing, and there is a growing need for innovation and new technology solutions to produce amorphous solid dispersions.
In this webinar, the featured speaker will explore the latest trends and challenges in the development of poorly soluble molecules. The speaker will also introduce attendees to the KinetiSol Technology — a cutting-edge approach that overcomes the limitations of current amorphous dispersion technologies. This innovative and flexible solution revolutionizes the conventional manufacturing process of amorphous solid dispersions, paving the way for improved drug absorption and dosage forms.
Register for this webinar to learn how this next-generation technology for amorphous solid dispersions can help address the challenges of developing and manufacturing poorly soluble drugs. Learn about the benefits it can provide for the pharmaceutical industry as a whole.
Dave A. Miller, PhD, Chief Scientific Officer, AustinPx
Dr. Dave Miller brings over two decades of pharmaceutical development experience and has spent his career investigating ways to improve the bioavailability of poorly soluble molecules. As CSO of AustinPx, Dr. Miller leads the pharmaceutics and analytical development teams and oversees the application of the KinetiSol® Technology. Prior to his current position, Dr. Miller served as Vice President of Research and Development at DisperSol Technologies and Senior Principal Scientist at Hoffmann-La Roche. Dr. Miller specializes in formulation and processing technologies for improving oral bioavailability of insoluble small molecules. He has applied his expertise toward advancing numerous drug candidates through all stages of development from early discovery to line extension. Dr. Miller is a co-inventor of the pharmaceutical applications of the KinetiSol technology and continues to be a key innovative driver for application and expansion of the platform.
He has published over 40 research articles in peer-reviewed journals, authored eight book chapters and is co-editor of the First, Second and Third Editions of the textbook, Formulating Poorly Water-Soluble Drugs. He is a co-inventor on numerous granted and pending patents worldwide.
Dr. Miller holds a BS in chemical engineering and a PhD in pharmaceutics from the University of Texas at Austin.
Who Should Attend?
This webinar will appeal to senior-level professionals working in pharmaceutical manufacturing and supply chain with the following or related job titles:
- Director/Senior Director/Vice President, R&D
- Director/Senior Director/Vice President, CMC
- Manager/Director/Senior Director, Procurement & Sourcing
- Director/Senior Director, Product Development
- Director/Senior Director, Supply Chain
What You Will Learn
- Review current technologies for the development of amorphous solid dispersions and trends leading to more difficult to develop molecules
- Explore challenges with current amorphous dispersion manufacturing technologies
- Be introduced to a next-generation amorphous dispersion technology and how is it different from other technologies
- Explore ways to determine when to choose this unique and highly optimized technology
- Get an overview of the technology development process and scale-up methodologies
- Review case studies demonstrating the performance of drugs formulated using this cutting-edge technology
Founded in 2007, AustinPx, Pharmaceutics and Manufacturing, is a fee-for-service CDMO offering preclinical through Phase II formulation and process development and GMP manufacturing of oral dosage forms. We specialize in bioavailability enhancement, speed to clinic and market development strategies, and dose form development.
The name AustinPx represents where we come from and what we do. Px stands for Pharmaceutics. To our core, we are a pharmaceutics company. Our approach is data-driven and agnostic which means our formulation strategy for each drug is based on the unique physiochemistry of that compound. And for poorly soluble compounds, we have one of the most powerful tools available in KinetiSol, a truly next generation technology for rendering active pharmaceutical ingredients amorphous.